Similarly, studies in tendinopathy models identified sST2 as one of the targets of miRNA-29; increased IL-33 release during tendon injury was reported to downregulate miRNA-29a expression, thereby leading to elevated sST2 levels [39,67]. This evidence concerns the gene IL33 and disease of the tendon.